Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain scans reveal hidden vascular clues in early Alzheimer's

NCT ID NCT06322121

Knowledge-focused Sponsor: Leiden University Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study uses MRI scans to track how blood vessels in the brain change over time in people with early Alzheimer's disease and healthy volunteers. Researchers aim to understand if reduced blood vessel reactivity is an early sign of dementia. The study involves 120 participants and does not test any drug or treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help identify early markers for dementia and guide future treatments targeting blood vessel health.
What could go wrong
This is an observational study, not a treatment trial. It may not lead directly to new therapies, and results may not apply to all dementia patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2023

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients who attended a memory clinic and healthy controls

Ages

50 to 90 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * For this study three different routes for inclusion exists. Inclusion criteria for each group separately are shown below. 1. Participants who were included in our previous CASCADE study (P19.039). * Capable of giving informed consent (see appendix) 2. Patients who attended a memory clinic within one year ago * Diagnosed with (mixed) probable AD * Diagnosed as MCI * Diagnosed as SCI * Age between 50-90 years * Capable of giving informed consent (see appendix) 3. Control subjects * Healthy adults without memory complaints * Age between 50 -90 years * Capable of giving informed consent Exclusion Criteria: * Contra-indication to MRI scanning: * Claustrophobia * Pacemakers and defibrillators * Nerve stimulators * Intracranial clips * Intraorbital or intraocular metallic fragments * Cochlear implants * Ferromagnetic implants * Hydrocephaluspump * Intra-utrine device (not all types) Permanent make-up * Tattoos above the shoulders (not all) * Specific contraindications to fMRI * Seizure within prior year. * Noncorrectable visual impairment. * MMSE \< 19 points (measured at moment of screening or at memory clinic with a maximum of 6 months in retrospect) * Severe physical restrictions (completely wheelchair dependent) * Age above 90

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Alzheimer disease dementia subjective cognitive decline

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dementia

Contacts and locations

Locations

  • Leids Universitair Medisch Centrum

    Leiden, 2333 ZA, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.